Company Overview - Lumexa Imaging Holdings, Inc. is one of the largest providers of outpatient imaging services in the United States [1] - As of September 30, 2025, the company operates the second largest outpatient imaging center footprint in the country, with 184 centers across 13 states [2] - The company has eight joint venture partnerships with health systems [2] Upcoming Events - Caitlin Zulla, CEO, and Tony Martin, CFO, will participate in the 44th Annual J.P. Morgan Healthcare Conference [1] - The presentation is scheduled for January 12, 2026, at 7:30am PST [1] - A webcast link and related presentation materials will be available online [1]

Core Thesis - RadNet, Inc. is facing significant challenges as its core business and newly rebranded Digital Health segment show a disconnect between market hype and actual performance [2][5]. Financial Performance - RadNet's share price was $71.22 as of December 16th, with a trailing P/E ratio of 386.89 [1]. - The company generated approximately $1.5 billion in revenue during the first nine months of 2025, with less than 5% ($65 million) coming from the Digital Health segment [3]. - Revenue growth metrics are inflated due to consolidations of neighboring centers, with reported same-center sales growth of 6%–10% masking underlying stagnation [4]. Digital Health Segment - The Digital Health segment's growth is primarily driven by intercompany sales to RadNet's own imaging centers, with minimal external adoption and only one notable outside customer [3]. - Despite marketing AI-powered tools as transformative, external traction among corporate clients has been limited [3]. Financial Health and Reporting Issues - Adjusted EBITDA margins suggest profitability improvements, but corrected figures indicate that margins are actually contracting, revealing financial fragility [4]. - Inconsistencies in financial filings, including conflicting counts of operational centers and divergent revenue figures, highlight chaotic bookkeeping and opaque reporting practices [4]. Insider Activity and Market Sentiment - Insider selling has totaled over 780,000 shares worth $50.9 million in the past two years, raising concerns about the motivations of those closest to the company [5]. - The imaging center business is under persistent reimbursement pressure from Medicare and commercial payers, limiting sustainable growth [5]. - The stock is perceived to be trading well above intrinsic value, driven more by hype than by operational execution or durable revenue streams [5].

Core Insights - Lumexa Imaging Holdings (LMRI) experienced modest gains on its first day of trading, indicating a positive market reception for the company [1] - The company is positioned for growth through mergers and acquisitions in the diagnostic imaging services sector, highlighting the importance of the offering proceeds for its operational management [1] Company Overview - Lumexa Imaging Holdings is focused on the diagnostic imaging services industry, which is currently undergoing M&A-driven growth [1] - The company aims to leverage the capital raised from its initial public offering to enhance its operational capabilities and manage its growth strategy effectively [1] Market Context - The IPO market is seeing increased activity, with companies like Lumexa Imaging Holdings seeking to capitalize on favorable conditions for raising capital through public offerings [1] - The diagnostic imaging services sector is highlighted as a critical area for investment, driven by ongoing consolidation and the need for enhanced service offerings [1]

Core Viewpoint - Lumexa Imaging's shares experienced a slight increase during their debut on Nasdaq, leading to a market valuation of $1.76 billion for the company [1] Company Summary - Lumexa Imaging is a provider of diagnostic imaging services [1] - The company's market valuation reached $1.76 billion following its initial public offering [1]

Core Points - Lumexa Imaging Holdings, Inc. has announced the pricing of its initial public offering (IPO) at $18.50 per share for 25,000,000 shares of common stock [1] - The IPO includes a 30-day option for underwriters to purchase an additional 3,750,000 shares [1] - Trading is expected to commence on the Nasdaq Global Select Market under the symbol "LMRI" on December 11, 2025, with the offering closing on December 12, 2025, pending customary closing conditions [1] Company Overview - Lumexa Imaging is a nationwide provider of diagnostic imaging services, operating the second largest outpatient imaging center footprint in the United States as of September 30, 2025 [5] - The company operates 184 centers across 13 states and has eight joint venture partnerships with health systems [5]

Table of Contents As filed with the Securities and Exchange Commission on December 2, 2025 Registration No. 333-291590 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Lumexa Imaging Holdings, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 8071 41-2605845 (I.R.S. ...

Core Insights - RadNet, Inc. is a key player in the healthcare sector, focusing on diagnostic imaging services through a network of outpatient imaging centers, offering MRI, CT, and PET scans, with a subsidiary, DeepHealth, enhancing its services with AI technology [1] Group 1: Stock Performance and Ratings - On December 1, 2025, B. Riley upgraded RadNet's stock to a "Buy" rating, raising the price target from $71 to $87, reflecting confidence in the company's growth potential [2][6] - Despite the upgrade, RadNet's stock is currently priced at $81.67, showing a decrease of 1.35% from the previous day, with a market capitalization of approximately $6.3 billion [4][6] Group 2: Innovations and Strategic Focus - DeepHealth has launched an expanded portfolio of next-generation imaging informatics and clinical AI solutions at RSNA 2025, aimed at improving disease detection, assessment, and monitoring [3] - The President and CEO of RadNet's Digital Health Division highlighted the transformative potential of AI-powered imaging, indicating that integrating AI across its portfolio could drive future growth [5]

Core Insights - Baron Health Care Fund reported a 5.39% increase in Q3 2025, slightly outperforming the Russell 3000 Health Care Index which gained 5.05% [1] - The fund's performance was impacted by stock selection and negative effects from active sub-industry allocations and cash holdings during a rising market [1] Fund Performance - The Baron Health Care Fund's Institutional Shares rose 5.39% in Q3 2025 [1] - The Russell 3000 Index gained 8.18% during the same period [1] - Solid stock selection was offset by negative impacts from allocations and cash holdings [1] Company Highlight: RadNet, Inc. - RadNet, Inc. is the largest operator of outpatient diagnostic imaging services in the U.S. [3] - The company's stock closed at $77.82 on November 3, 2025, with a market capitalization of $6 billion [2] - RadNet's shares gained 14.36% over the last 52 weeks, despite a slight decline of 0.12% in the last month [2] Financial Performance of RadNet, Inc. - RadNet reported an 8.4% revenue growth and a 12.3% increase in EBITDA, exceeding consensus estimates by 2% and 6% respectively [3] - Total imaging volume grew by 4.9%, with same-store advanced imaging growth accelerating to 6.6% [3] - The Digital Health segment saw revenue increase by approximately 31% [3] Future Outlook for RadNet, Inc. - Management anticipates a 3.3% Medicare rate hike in 2026 and plans to expand MRI and ultrasound capacity through AI upgrades [3] - The company has a strong pipeline with 11 new sites planned for both 2025 and 2026 [3] - Long-term conviction in RadNet is supported by demographic trends and operational scale [3]

Company Overview - RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States, based on the number of locations and annual imaging revenue [3] - The company operates a network of 398 owned and/or operated outpatient imaging centers across several states, including Arizona, California, Delaware, Florida, Maryland, New Jersey, New York, and Texas [3] - RadNet employs over 11,000 individuals, including full-time and per diem employees and technologists [3] Upcoming Events - Mark Stolper, Executive Vice President and Chief Executive Officer of RadNet, will present virtually at the 35th Oppenheimer Healthcare MedTech & Services Conference on March 17, 2025, at 12:40 p.m. Eastern Time [1] - A live webcast of the presentation will be available for access and replay [2]